Zacks: Analysts Expect Aptinyx Inc (NASDAQ:APTX) Will Post Earnings of -$0.30 Per Share

Share on StockTwits

Equities analysts predict that Aptinyx Inc (NASDAQ:APTX) will report earnings per share of ($0.30) for the current quarter, according to Zacks. Three analysts have made estimates for Aptinyx’s earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.33). Aptinyx posted earnings of ($0.44) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 31.8%. The business is expected to issue its next earnings results on Tuesday, November 10th.

According to Zacks, analysts expect that Aptinyx will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.34) to ($1.15). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.29) per share, with EPS estimates ranging from ($1.80) to ($0.97). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Thursday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.01. The company had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.84 million. Aptinyx had a negative return on equity of 49.15% and a negative net margin of 1,764.55%.

APTX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Aptinyx in a report on Wednesday. They set a “neutral” rating on the stock. William Blair reiterated a “buy” rating on shares of Aptinyx in a report on Thursday, October 1st. BMO Capital Markets reiterated a “buy” rating and set a $13.00 price target on shares of Aptinyx in a report on Friday, August 14th. Zacks Investment Research upgraded Aptinyx from a “sell” rating to a “hold” rating in a report on Monday, July 20th. Finally, SunTrust Banks initiated coverage on Aptinyx in a report on Wednesday, July 1st. They set a “buy” rating and a $15.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Aptinyx currently has an average rating of “Buy” and an average price target of $9.31.

Hedge funds and other institutional investors have recently modified their holdings of the business. Meridian Wealth Management LLC lifted its position in shares of Aptinyx by 100.0% during the 3rd quarter. Meridian Wealth Management LLC now owns 60,000 shares of the company’s stock worth $202,000 after purchasing an additional 30,000 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Aptinyx by 5.0% in the 2nd quarter. Two Sigma Advisers LP now owns 105,800 shares of the company’s stock valued at $441,000 after acquiring an additional 5,000 shares in the last quarter. Nuveen Asset Management LLC acquired a new position in Aptinyx in the 2nd quarter valued at approximately $574,000. Charles Schwab Investment Management Inc. acquired a new position in Aptinyx in the 2nd quarter valued at approximately $294,000. Finally, Jane Street Group LLC raised its holdings in Aptinyx by 46.4% in the 2nd quarter. Jane Street Group LLC now owns 50,503 shares of the company’s stock valued at $210,000 after acquiring an additional 15,999 shares in the last quarter. Hedge funds and other institutional investors own 59.26% of the company’s stock.

Shares of Aptinyx stock traded down $0.05 on Friday, reaching $3.73. 63,036 shares of the company were exchanged, compared to its average volume of 301,637. The stock has a fifty day moving average price of $3.39 and a 200-day moving average price of $3.59. The firm has a market capitalization of $175.17 million, a price-to-earnings ratio of -2.55 and a beta of 1.21. Aptinyx has a fifty-two week low of $1.60 and a fifty-two week high of $5.28.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Story: What defines an oversold asset?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.